Furthermore, a major drawback of GLP-1 agonist drugs is a high incidence of gastrointestinal problems, like nausea, vomiting, diarrhoea, and constipation
By the end of 2035, it is expected to surpass US$ 132.79 billion, growing steadily at a CAGR of 9.63%
This category includes compounds such as semaglutide, tirzepatide, retatrutide, cagrilintide, and orforglipron, each associated with GLP-1 receptor activity and related metabolic pathway research
Clinical data shows that 30 to 40 percent of users lose 5 to 10 percent of body weight on the starting dose, while others see minimal results initially
[Nourishes Gut Lining & Microbiome] Akkermansia, probiotics, polyphenols from pomegranate and grape seed work together as gut health supplements to support barrier integrity and promote microbial diversity
The staff is professional and extremely knowledgeable